Evolent Health

EOLS Micro Cap

Healthcare · Drug Manufacturers - Specialty & Generic

Updated: Apr 5, 2026, 17:43 UTC

$4.03

-6.5% today

52W: $3.86 – $12.28

52W Low: $3.86 Position: 2% 52W High: $12.28

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

16.79x

Forward Price/Earnings

P/S Ratio

0.88x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$262.2M

Market Capitalization

Revenue Growth

14.4%

YoY Revenue Growth

Profit Margin

-17.38%

Net profit margin

ROE

—

Return on Equity

Beta

Market sensitivity

Short Interest

11.95%

% of float sold short

Avg. Volume

1,310,345

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

6 analysts

Avg. Price Target

$14.67

+263.94% upside

Target Range

$10.00 – $20.00

About the Company

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Country: United States Employees: 334 Exchange: NGM